Informations générales (source: ClinicalTrials.gov)
An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome (aHUS Registry)
Observational [Patient Registry]
Alexion Pharmaceuticals, Inc. (Voir sur ClinicalTrials)
avril 2012
janvier 2031
19 juillet 2024
Post-marketing safety data on patients treated and untreated with eculizumab or
ravulizumab.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL NOVO | DEVAUD | 04/07/2024 11:05:02 | Contacter | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Clinical Trial Site - 21079 - Dijon - France | Mousson | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 29609 - Brest - France | LeMeur | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 33076 - Bordeaux - France | Delmas | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 35203 - Rennes - France | Choukroun | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 38043 - Grenoble - France | Zaoui | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 49933 - Angers - France | Subra | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 59037 - Lille - France | Provot | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 59322 - Valenciennes - France | Haeck | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 63000 - Clermont-Ferrand - France | Heng | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 64109 - Bayonne - France | Lacraz | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 69677 - Bron - France | Sellier-LeClerc | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 73011 - Chambéry - France | Bally | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 80054 - Amiens - France | Djeddi | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - 94270 - Le Kremlin-Bicêtre - France | Durrbach | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Lille - France | Contact (sur clinicalTrials) | ||||
| Clinical Trial Site - Lyon - France | Jolivot | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Marseille - France | Rousset-Rouviere | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Montpellier - France | Fila | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Nice - France | Seitz-Polski | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Perpignan - France | Vela | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Poitiers - France | Bridoux | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Pontoise - France | Devaud | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Rennes - France | Vigneau | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Rouen - France | Lebourg | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Strasbourg - France | Moulin | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Toulouse - France | Kamar | Contact (sur clinicalTrials) | |||
| Clinical Trial Site - Tours - France | Halimi | Contact (sur clinicalTrials) | |||
| Clinical Trial Site 1 - 44035 - Nantes - France | Fakhouri | Contact (sur clinicalTrials) | |||
| Clinical Trial Site 1 - 54511 - Nancy - France | Frimat | Contact (sur clinicalTrials) | |||
| Clinical Trial Site 1 - 75935 - Paris - France | Deschenes | Contact (sur clinicalTrials) | |||
| Clinical Trial Site 2 - 75015 - Paris - France | Legendre | Contact (sur clinicalTrials) | |||
| Clinical Trial Site 3 - 75970 - Paris - France | Rondeau | Contact (sur clinicalTrials) | |||
| Clinical Trial Site 4 - 75015 - Paris - France | Thervet | Contact (sur clinicalTrials) | |||
| Clinical Trial Site 5 - 75743 - Paris - France | Boyer | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Male or female patients of any age, including minors, who have been diagnosed with
aHUS
- Patients with or without an identified complement pathogenic variant or
anti-complement factor antibody
- Able to give written informed consent. Patient or patient's parent/legal guardian
must be willing and able to given written informed consent and the patient (if
minor) must be willing to give written informed assent [if applicable as determined
by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)].
- ADAMTS13 > 5%, if performed.
- Male or female patients of any age, including minors, who have been diagnosed with
aHUS
- Patients with or without an identified complement pathogenic variant or
anti-complement factor antibody
- Able to give written informed consent. Patient or patient's parent/legal guardian
must be willing and able to given written informed consent and the patient (if
minor) must be willing to give written informed assent [if applicable as determined
by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)].
- ADAMTS13 > 5%, if performed.
- Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin producing Escherichia coli
(STEC).
- Unable to give written informed consent. Patient or patient's parent/legal guardian
unable to give written informed consent. Patient (if minor) unable to give written
informed assent (if applicable as determined by the central Institutional Review
Boards/Independent Ethics Committees [IRB/IEC]).